| Karl Benjamin Genovese, MD | |
|
73 Waterbury Rd Ste 1, Prospect, CT 06712-1252 | |
| (203) 527-9444 | |
| Not Available |
| Full Name | Karl Benjamin Genovese |
|---|---|
| Gender | Male |
| Speciality | Family Practice |
| Experience | 7 Years |
| Location | 73 Waterbury Rd Ste 1, Prospect, Connecticut |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1396275244 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| Saint Mary's Hospital | Waterbury, CT | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Hartford Healthcare Medical Group Inc | 1153573902 | 221 |
News Archive
Axentis Pharma AG has initiated a clinical phase IIa trial to assess the safety and tolerability of a new therapeutic formulation for the treatment of severe pulmonary infection in cystic fibrosis patients. The new formulation allows an established therapeutic agent to be delivered directly to the site of infection. The forthcoming trial will also compare the effects of two different doses of the new drug.
Learning-related brain activity in Parkinson's patients improves as much in response to a placebo treatment as to real medication, according to a new study by researchers at the University of Colorado Boulder and Columbia University.
Researchers from the University of Twente's MIRA research centre, together with the VUmc, TU Delft and the Radboud umc, have developed the A-Gear: a robotic arm that can support the daily activities of people suffering the muscular disease Duchenne Muscular Dystrophy.
Though spinal muscular atrophy in its most severe form remains incurable and fatal in early childhood, researchers are sustaining a multipronged counterattack for patients and their families. The first treatment for the disease gained U.S. market approval in December.
Insomnia symptoms are often persistent, report researchers who found that targeting sleep-interfering behaviors may be one method of prevention.
› Verified 1 days ago
| Entity Name | Hartford Healthcare Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1043561301 PECOS PAC ID: 1153573902 Enrollment ID: O20121201000007 |
News Archive
Axentis Pharma AG has initiated a clinical phase IIa trial to assess the safety and tolerability of a new therapeutic formulation for the treatment of severe pulmonary infection in cystic fibrosis patients. The new formulation allows an established therapeutic agent to be delivered directly to the site of infection. The forthcoming trial will also compare the effects of two different doses of the new drug.
Learning-related brain activity in Parkinson's patients improves as much in response to a placebo treatment as to real medication, according to a new study by researchers at the University of Colorado Boulder and Columbia University.
Researchers from the University of Twente's MIRA research centre, together with the VUmc, TU Delft and the Radboud umc, have developed the A-Gear: a robotic arm that can support the daily activities of people suffering the muscular disease Duchenne Muscular Dystrophy.
Though spinal muscular atrophy in its most severe form remains incurable and fatal in early childhood, researchers are sustaining a multipronged counterattack for patients and their families. The first treatment for the disease gained U.S. market approval in December.
Insomnia symptoms are often persistent, report researchers who found that targeting sleep-interfering behaviors may be one method of prevention.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Karl Benjamin Genovese, MD 73 Waterbury Rd Ste 1, Prospect, CT 06712-1252 Ph: (203) 527-9444 | Karl Benjamin Genovese, MD 73 Waterbury Rd Ste 1, Prospect, CT 06712-1252 Ph: (203) 527-9444 |
News Archive
Axentis Pharma AG has initiated a clinical phase IIa trial to assess the safety and tolerability of a new therapeutic formulation for the treatment of severe pulmonary infection in cystic fibrosis patients. The new formulation allows an established therapeutic agent to be delivered directly to the site of infection. The forthcoming trial will also compare the effects of two different doses of the new drug.
Learning-related brain activity in Parkinson's patients improves as much in response to a placebo treatment as to real medication, according to a new study by researchers at the University of Colorado Boulder and Columbia University.
Researchers from the University of Twente's MIRA research centre, together with the VUmc, TU Delft and the Radboud umc, have developed the A-Gear: a robotic arm that can support the daily activities of people suffering the muscular disease Duchenne Muscular Dystrophy.
Though spinal muscular atrophy in its most severe form remains incurable and fatal in early childhood, researchers are sustaining a multipronged counterattack for patients and their families. The first treatment for the disease gained U.S. market approval in December.
Insomnia symptoms are often persistent, report researchers who found that targeting sleep-interfering behaviors may be one method of prevention.
› Verified 1 days ago
Renika N Mcleod-labissiere, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 115 Waterbury Road, Prospect, CT 06712 Phone: 203-758-5660 Fax: 203-758-3161 | |
Brittany Andreoli, DO Family Medicine Medicare: Medicare Enrolled Practice Location: 73 Waterbury Rd, Prospect, CT 06712 Phone: 518-264-2866 |